NeuroMetrix Announces that Frank McGillin will Participate in a Panel on the Future of Wearables at the 2016 International Consumer Electronics Show (CES)

Press Releases

NeuroMetrix Announces that Frank McGillin will Participate in a Panel on the Future of Wearables at the 2016 International Consumer Electronics Show (CES)

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin, Senior Vice President and General Manager, Consumer will participate in a panel titled "Wearables: Sleeker Smarter Faster" on Thursday, January 7 at 4:30pm (Pacific) at the 2016 CES Event in Las Vegas. Jane Francisco, Editor-in-Chief, Good Housekeeping will moderate the panel.

Mr. McGillin will join other industry leaders including Dr. Arshya Vahabzadeh, Innovation Officer and Physician, M.G.H./Harvard Medical School, Jorge Valdes, EVP, Chief Technical Officer, Dexcom Inc., Laurel A. Christensen, Ph.D., Chief Audiology Officer, GN ReSound Group and Dr. David L. Katz, Director, Yale-Griffin Prevention Research Center.

"CES is known for being at the cutting edge of consumer technology," said Mr. McGillin. "To become an indispensible part of our lives, future wearables will need to deliver relevant functionality that goes beyond the simple tracker and are designed to integrate seamlessly in your life. Products like Quell® are a good example of what is possible."

CES is the largest consumer technology event and has served as the launch pad for innovators and breakthrough technologies for almost 50 years. CES attracts global business leaders and pioneering thinkers to a forum where the industry's most relevant issues are addressed.

CES attendees will have an opportunity to learn about Quell, the NeuroMetrix wearable device for treating chronic pain. The Company will offer a first glimpse of the latest generation of Quell technology at Booth # 73313 in the Digital Health section of CES.

About Quell

Quell utilizes NeuroMetrix's patented neurostimulation technology to provide widespread relief from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell includes a smartphone app that tracks and personalizes their pain therapy. It is available for purchase at QuellRelief.com, selected retailers and healthcare professionals.

About NeuroMetrix
NeuroMetrix is an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media